- TWD19.08bn
- TWD16.52bn
- TWD1.01bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.16 | ||
| Price to Tang. Book | 2.16 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 19.64 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -9.56% | ||
| Return on Equity | -8% | ||
| Operating Margin | -99.11% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | TWDm | 1,071.84 | 1,697.36 | 1,481.02 | 1,022.65 | 1,008.96 | 1,488 | n/a | 16.21% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
EirGenix Inc is a Taiwan-based company primarily engaged in the development of antibody drugs and the manufacture of biopharmaceuticals. Its main businesses include the provision of Contract Development & Manufacturing Organization (CDMO) services, the construction of cell strain, the manufacture of clinical trial medicine, analytical science and protein identification, and PIC/S manufacturing plant to provide clinical trial drug production.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- December 21st, 2012
- Public Since
- November 23rd, 2016
- No. of Employees
- 207
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Taiwan Stock Exchange- Shares in Issue
- 302,338,000
- Address
- NEW TAIPEI, 221
- Web
- https://www.eirgenix.com/
- Phone
- +886 277080123
- Contact
- Lee-Cheng Liu
- Auditors
- PricewaterhouseCoopers LLP
Similar to 6589
Adimmune
Taiwan Stock Exchange
Bora Pharmaceuticals Co
Taiwan Stock Exchange
BRIM Biotechnology
Taiwan Stock Exchange
Caliway Biopharmaceuticals Co
Taiwan Stock Exchange
Cenra
Taiwan Stock Exchange
FAQ
As of Today at 20:23 UTC, shares in EirGenix are trading at TWD63.10. This share price information is delayed by 15 minutes.
Shares in EirGenix last closed at TWD63.10 and the price had moved by -29.1% over the past 365 days. In terms of relative price strength the EirGenix share price has underperformed the FTSE Developed Asia Pacific Index by -36.16% over the past year.
The overall consensus recommendation for EirGenix is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreEirGenix does not currently pay a dividend.
EirGenix does not currently pay a dividend.
EirGenix does not currently pay a dividend.
To buy shares in EirGenix you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of TWD63.10, shares in EirGenix had a market capitalisation of TWD19.08bn.
Here are the trading details for EirGenix:
- Country of listing: Taiwan
- Exchange: TAI
- Ticker Symbol: 6589
Based on an overall assessment of its quality, value and momentum EirGenix is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in EirGenix is TWD138.00. That is 118.7% above the last closing price of TWD63.10.
Analysts covering EirGenix currently have a consensus Earnings Per Share (EPS) forecast of -TWD0.90 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like EirGenix. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -34.48%.
As of the last closing price of TWD63.10, shares in EirGenix were trading -14.51% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The EirGenix PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at TWD63.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on EirGenix's directors